How the EU’s new privacy laws could actually boost Facebook and Google
The Wall Street Journal and New York Times have both published reports outlining how new rules, widely expected to rein in Big Tech, could have the opposite effect.
Backstory: On May 25, the EU enforces its General Data Protection Regulation—rules that will often require firms to gain consent if they plan to use an EU resident’s personal information. It’s thought that it could help clean up the acts of Facebook et al.
The problems: The Times notes, though, that “wary consumers are more prone to trust recognized names with their information than unfamiliar newcomers.” The Journal, meanwhile, says big firms will use “a relatively strict interpretation of the new law ... setting an industry standard that is hard for smaller firms to meet.”
Plus: EU official Věra Jourová points out to the Journal that Google and Facebook “have the money, an army of lawyers, an army of technicians and so on” to make the process of transition realtively easy.
Why it matters: All those factors could mean that smaller firms struggle to accommodate the new rules, while Facebook and Google prosper and consolidate their advertising duopoly.
But: Now more than ever, Facebook and others are under scrutiny about how they use data. While GDPR may play to their advantage in some ways, lawyers, politicians, and activists will be ready to pounce the next time things go wrong.
Keep Reading
Most Popular

Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.